Feb 09, 2023 / 02:00PM GMT
Charles Zhu - Guggenheim Securities - Analyst
Good morning, everyone, and thank you for joining us for our next discussion. Also very timely coming off of our prostate cancer panel just now. I'm Charles Zhu, one of the senior biotech analysts at Guggenheim Securities.
With us here today from ESSA Pharma are David as well as Peter. Thank you for joining us. Perhaps just to get us started off, could you give us some background into your company, platform, and pipeline, please?
David Parkinson - ESSA Pharma Inc. - President, CEO, & Director
Certainly. Well, first of all, we're delighted to be here this morning, and we've just had a wonderful discussion, panel discussion, that we listened to about current approaches in prostate cancer. And at ESSA, we're involved in one of the main areas that was addressed in that panel discussion, which is the fact that prostate cancer is predominantly AR-driven, androgen receptor-driven, and that there is a huge unmet medical need because all men become resistant ultimately to the current anti-androgens that are being
ESSA Pharma Inc at Guggenheim Healthcare Talks Oncology Day Transcript
Feb 09, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers